Health · Medical Research · 1 hr ago
BeOne Presents Early Cancer Drug Data at ESMO 2026
BeOne Medicines shared new data on experimental cancer drugs at the ESMO 2026 congress in Madrid.
The presentations covered potential treatments for liver, lung and other cancers.
One investigational drug, designed to target GPC3 and 4-1BB, produced a 36% confirmed response rate at its Phase 3 dose in heavily pretreated liver cancer patients.
The company also described its safety profile as favorable, but the information provided does not give further details.
Other presentations included early findings on a brain-penetrant drug for cancers with MTAP deficiency and an antibody-drug conjugate for a type of lung cancer.
The findings are from investigational medicines, so they do not establish that the drugs are effective or approved treatments.
The congress is scheduled to run from October 23 to 27, 2026, and no further next steps were stated.
BeOne Medicines announced new data from investigational cancer medicines at the 2026 European Society for Medical Oncology Congress.
The data cover gastrointestinal, lung and breast cancers.
A GPC3 x 4-1BB bispecific recorded a 36% confirmed response rate at its Phase 3 dose in heavily pretreated liver cancer, according to the release.
The release also described promising antitumor and central nervous system activity for a brain-penetrant PRMT5 inhibitor.
It reported first clinical data for a CEA-targeting ADC, with encouraging and sustained responses in CEA-high non-small cell lung cancer.
- Who
- BeOne Medicines Ltd., a global oncology company.
- What
- It announced new data from multiple investigational medicines for solid tumors.
- When
- The announcement was published on October 24, 2026. The congress ran October 23–27, 2026.
- Where
- The data were presented at the ESMO Congress in Madrid.
- Why
- Not stated.
This story does not have two clearly opposing sides.
The ESMO Congress took place in Madrid.
BeOne announced new data from investigational medicines across solid tumor disease areas.
- Response rate
- 36% confirmed at the GPC3 x 4-1BB bispecific’s Phase 3 dose
- Cancer setting
- Heavily pretreated liver cancer
- PRMT5 inhibitor
- Brain-penetrant; antitumor and CNS activity described as promising
- ADC target
- CEA
- Lung cancer
- CEA-high NSCLC
- Congress
- ESMO 2026, Madrid, October 23–27